Sensus Healthcare (SRTS) Expected to Announce Earnings on Thursday

Sensus Healthcare (NASDAQ:SRTS) is expected to be issuing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.1250) per share and revenue of $5.3230 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.The business had revenue of $4.94 million during the quarter, compared to the consensus estimate of $8.35 million.

Sensus Healthcare Trading Down 0.6%

SRTS stock traded down $0.03 during trading on Wednesday, reaching $3.91. 19,149 shares of the stock were exchanged, compared to its average volume of 76,772. The firm’s 50 day moving average is $4.13 and its 200 day moving average is $4.14. The firm has a market cap of $64.28 million, a P/E ratio of -8.22 and a beta of 1.19. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $5.92.

Analyst Upgrades and Downgrades

SRTS has been the topic of several analyst reports. Maxim Group cut their target price on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Tuesday, April 21st. Alliance Global Partners began coverage on shares of Sensus Healthcare in a research note on Friday, March 6th. They issued a “buy” rating and a $7.50 target price for the company. Finally, Wall Street Zen downgraded shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.88.

Institutional Trading of Sensus Healthcare

A number of institutional investors have recently modified their holdings of the business. Greenline Wealth Management LLC bought a new position in Sensus Healthcare in the 4th quarter worth about $513,000. Rothschild Wealth LLC purchased a new position in Sensus Healthcare during the 4th quarter valued at about $500,000. Ingalls & Snyder LLC bought a new stake in shares of Sensus Healthcare during the fourth quarter valued at about $219,000. Jane Street Group LLC purchased a new stake in shares of Sensus Healthcare in the fourth quarter worth about $79,000. Finally, XTX Topco Ltd purchased a new stake in shares of Sensus Healthcare in the fourth quarter worth about $77,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.